By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dicerna Pharmaceuticals 

480 Arsenal Street
Building 1, Suite 120
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-621-8097 Fax: n/a


Start Up

Company News
Dicerna (DRNA) Announces Pricing Of Follow-On Offering Of Common Stock 5/21/2015 11:56:24 AM
Dicerna (DRNA) Announces Follow-On Public Offering Of Common Stock 5/19/2015 1:15:49 PM
Dicerna (DRNA) To Present Interim Clinical Data From First DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting 5/14/2015 12:18:49 PM
Dicerna (DRNA) Announces Expansion Of Ongoing DCR-MYC Phase 1 Study To Evaluate Safety And Efficacy In Patients With Advanced Pancreatic Neuroendocrine Tumors (PNETs) 5/14/2015 10:45:26 AM
Dicerna (DRNA) Announces First Quarter 2015 Financial And Operational Results 5/12/2015 10:51:20 AM
Dicerna (DRNA) Announces Potent, Durable Knockdown Of Gene Expression In Non-Human Primates With DsiRNA-EX Conjugates Being Investigated For Treatment Of Primary Hyperoxaluria Type 1 (PH1) 5/6/2015 9:42:53 AM
Dicerna (DRNA) To Present At The 17th Annual TIDES: Oligonucleotide And Peptide Therapeutics From Research Through Commercialization Conference 5/4/2015 8:34:46 AM
Dicerna (DRNA) To Announce First Quarter 2015 Financial Results And Host Conference Call On May 11, 2015 4/30/2015 12:26:49 PM
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna (DRNA)’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 4/23/2015 8:21:58 PM
Dicerna (DRNA) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 4/1/2015 3:34:17 PM